LICR stated has partnered with Cancer Research Institute to establish the Cancer Vaccine Collaborative, a coordinated global network of laboratory and clinical sites with expertise in immunology, to develop therapeutic cancer vaccines.
Ralph Venhaus, head of clinical and regulatory affairs at LICR, said: “After evaluating numerous EDC systems for their rigor as well as usability and accessibility, it became clear that Medidata offered the technology and support that would enable organisational growth.
“LICR also collaborates with commercial pharmaceutical partners. With Medidata’s broad usage in the commercial world, we believe this commonality of platform and underlying data standards will benefit researchers as well as patients.”
Tarek Sherif, chairman and CEO of Medidata Solutions, said: “As a research center working to translate its laboratory advances into human treatments in research settings, the Ludwig Institute for Cancer Research is taking on an effort in an already complex therapeutic area.
“Our experience in development of oncology treatments in both non-profit and commercial settings makes us a natural partner to support LICR’s clinical goals, and we look forward to helping drive their important research initiatives forward.”
